参考文献/References:
[1]Schefold J C, Filippatos G, Hasenfuss G, et al. Heart failure and kidney dysfunction: epidemiology, mechanisms and management[ J] . Nat Rev Nephrol, 2016, 12( 10) :610 -623.
[2]Adams K J, Fonarow G C, Emerman C L, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100, 000 cases in the Acute Decompensated Heart Failure National Registry ( ADHERE) [ J] . Am Heart J, 2005,149( 2) :209 -216.
[3]McAlister F A, Ezekowitz J, Tonelli M, et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study[ J] . Circulation, 2004,109( 8) :1004 -1009.
[4]Gansevoort R T, Correa - Rotter R, Hemmelgarn B R, etal. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention[ J] . Lancet, 2013,382( 9889) :339 -352.
[5]Sud M, Tangri N, Pintilie M, et al. ESRD and death after heart failure in CKD[ J] . J Am Soc Nephrol, 2015, 26( 3) :715 -722.
[6]Ronco C, Di Lullo L. Cardiorenal Syndrome in Western Countries: Epidemiology, Diagnosis and Management Approaches[ J] . Kidney Dis ( Basel) , 2017, 2 ( 4) : 151-163.
[7]Ronco C, McCullough P, Anker S D, et al. Cardio - renal syndromes: report from the consensus conference of the acute dialysis quality initiative [ J] . Eur Heart J,2010,31( 6) :703 -711.
[8]Takahama H, Nishikimi T, Takashio S, et al. Change in the NT - proBNP/ Mature BNP Molar Ratio Precedes Worsening Renal Function in Patients With Acute Heart Failure: A Novel Predictor Candidate for Cardiorenal Syndrome[ J] . J Am Heart Assoc, 2019,8( 17) : e11468.
[9]Sheng X, Lin L, Guo F, et al. Copeptin level in the early prediction of cardiorenal syndrome in rats[ J] . Exp Ther Med, 2018,16( 2) :937 -944.
[10]Schefold J C, Filippatos G, Hasenfuss G, et al. Heart failure and kidney dysfunction: epidemiology, mechanisms and management[ J] . Nat Rev Nephrol, 2016, 12( 10) :610 -623.
[11]Virzi G M, Breglia A, Brocca A, et al. Levels of Proinflammatory Cytokines, Oxidative Stress, and Tissue Damage Markers in Patients with Acute Heart Failure with and without Cardiorenal Syndrome Type 1 [ J] . Cardiorenal Med, 2018,8( 4) :321 -331.
[12]Linhart C, Ulrich C, Greinert D, et al. Systemic inflammation in acute cardiorenal syndrome: an observational pilot study[ J] . ESC Heart Fail, 2018,5( 5) :920 -930.
[13]Volpe M, Carnovali M, Mastromarino V. The natriureticpeptides system in the pathophysiology of heart failure:from molecular basis to treatment[ J] . Clin Sci ( Lond) ,2016,130( 2) :57 -77.
[14]Clementi A, Virzi G M, Battaglia G G, et al. Neurohormonal, Endocrine, and Immune Dysregulation and Inflammation in Cardiorenal Syndrome[ J] . Cardiorenal Med,2019,9( 5) :265 -273.
[15]Zannad F, Rossignol P. Cardiorenal Syndrome Revisited[ J] . Circulation, 2018,138( 9) :929 -944.
[16]李鹤,刘亚洋.益气强心方对 1型心肾综合征病人心肾功能的影响 [J].中西医结合心脑血管病杂志,2019,17(9):1390-1391.
[17]张群生.温阳益气活血方辅治Ⅱ型心肾综合征对心功能及肾功能影响[J].实用中医药杂志,2019,35(8):999-1000.
[18]冯伟,张晶,方芳.益气温阳活血利水方干预心肾综合征患者心肾功能的临床研究[J].中国循证心血管医学杂志,2019,11(9):1096-1098.
[19]王慧敏,吴英智,韦震鸣,等.真武汤治疗Ⅱ型及Ⅳ型心肾综合征的临床研究[J].实用医学杂志,2018,34(13):2255-2259.
[20]王海霞,牛燕运.温阳益气活血法对Ⅱ型心肾综合征病人心功能及肾功能的影响[J].中西医结合心脑血管病杂志,2018,16(17):2537-2539.
[21]张秀荣,薛一涛.真武汤合保元汤对 2型心肾综合征阳气亏虚证兼血瘀证心肾功能的影响[J].中国实验方剂学杂志,2018,24(9):202-207.
相似文献/References:
[1]黎美娟 叶明花 郑江明.脐疗治未病机理初探[J].陕西中医药大学学报,2019,(02):032.[doi:10.13424/j.cnki.jsctcm.2019.02.011]
[2]张秀琳汪茂荣.单味中药对酒精性肝病的治疗作用研究进展[J].陕西中医药大学学报,2021,(04):124.[doi:10.13424/j.cnki.jsctcm.2021.04.028]
[3]曹蓓苓 潘赐明 杨晓洁 范瀚中 李奇奇 夏雨欣 陈文慧.基于生物信息技术研究川芎-防风-麻黄角药治疗缺血性脑卒中的机制[J].陕西中医药大学学报,2022,(06):091.[doi:10.13424/j.cnki.jsctcm.2022.06.018]
[4]许飞 李学军.中药复方防治胃癌研究进展[J].陕西中医药大学学报,2022,(06):155.[doi:10.13424/j.cnki.jsctcm.2022.06.031]
[5]常小凡 谢西梅 唐园园 李秋宇 白秀 沈亚亭.针灸治疗新型冠状病毒肺炎文献研究概况[J].陕西中医药大学学报,2023,(04):007.[doi:10.13424/j.cnki.jsctcm.2023.04.002]
CHANG Xiaofan XIE XimeiTANG Yuanyuan LI Qiuyu BAI Xiu SHEN Yating.Overview of Literature Research on Acupuncture and Moxibustion Treatment of COVID-19[J].Journal of Shaanxi University of Traditional Chinese Medicine,2023,(01):007.[doi:10.13424/j.cnki.jsctcm.2023.04.002]
[6]杨康迪王一川张旭邵明聪李梓嫣王丽娜.温热类中药在治疗原发性肝癌中的应用及机制[J].陕西中医药大学学报,2024,(04):018.[doi:10.13424/j.cnki.jsctcm.2024.04.004]
YANG KangdiWANG YichuanZHANG XuSHAO MingcongLI ZiyanWANG Lina.Application and Mechanism of Warm Traditional Chinese Medicine in the Treatment of Primary Liver Cancer[J].Journal of Shaanxi University of Traditional Chinese Medicine,2024,(01):018.[doi:10.13424/j.cnki.jsctcm.2024.04.004]
[7]许飞李学军刘婕李让亮孙傲李悦罗玲.单味中药提取物治疗非酒精性脂肪性肝病 作用机制的研究进展[J].陕西中医药大学学报,2024,(04):137.[doi:10.13424/j.cnki.jsctcm.2024.04.027]
[8]张雨涵 王欣 史磊磊 张雪 李溪 张雪航 刘继平.糖尿病认知障碍的中医药研究进展[J].陕西中医药大学学报,2024,(05):008.[doi:10.13424/j.cnki.jsctcm.2024.05.002]
ZHANG Yuhan WANG Xin SHI Leilei ZHANG Xue LI Xi ZHANG Xuehang LIU Jiping.Research Progress of Traditional Chinese Medicine on Cognitive Impairment of Diabetes[J].Journal of Shaanxi University of Traditional Chinese Medicine,2024,(01):008.[doi:10.13424/j.cnki.jsctcm.2024.05.002]
[9]王人杰谌晓莉杨冰洋汪皓宇张业清.基于网络药理学和分子对接法研究肺清合剂治疗支气管扩张症的机制[J].陕西中医药大学学报,2024,(06):077.[doi:10.13424/j.cnki.jsctcm.2024.06.014]